AZD1775 targets the cell cycle checkpoint kinase Wee1 and potentiates genotoxic agent cytotoxicity through p53-dependent or -independent mechanisms. Here, we report that AZD1775 interacted synergistically with histone deacetylase inhibitors (HDACIs, for example, Vorinostat), which interrupt the DNA damage response, to kill p53-wild type (wt) or -deficient as well as FLT3-ITD leukemia cells in association with pronounced Wee1 inhibition and diminished cdc2/Cdk1 Y15 phosphorylation. Similarly, Wee1 shRNA knockdown significantly sensitized cells to HDACIs. Although AZD1775 induced Chk1 activation, reflected by markedly increased Chk1 S296/S317/S345 phosphorylation leading to inhibitory T14 phosphorylation of cdc2/Cdk1, these compensatory responses were sharply abrogated by HDACIs. This was accompanied by premature mitotic entry, multiple mitotic abnormalities and accumulation of early S-phase cells displaying increased newly replicated DNA, culminating in robust DNA damage and apoptosis. The regimen was active against patient-derived acute myelogenous leukemia (AML) cells harboring either wt or mutant p53 and various next-generation sequencing-defined mutations. Primitive CD34 + /CD123 + /CD38 − populations enriched for leukemiainitiating progenitors, but not normal CD34 + hematopoietic cells, were highly susceptible to this regimen. Finally, combining AZD1775 with Vorinostat in AML murine xenografts significantly reduced tumor burden and prolonged animal survival. A strategy combining Wee1 with HDACI inhibition warrants further investigation in AML with poor prognostic genetic aberrations.
INTRODUCTION
Acute myelogenous leukemia (AML) is a stem cell disorder resulting from differentiation and cell death program defects. Despite progress in elucidating AML molecular pathogenesis 1 and introduction of novel agents targeting mutant oncoproteins implicated in leukemogenesis (for example, FLT3-ITD), 2 the prognosis of patients with relapsed/refractory disease, particularly those ineligible for bone marrow transplantation, remains grim. 3 This has stimulated the development of epigenetically based therapies in AML, including DNMT1 and histone deacetylase inhibitors (HDACIs). 4 HDACIs induce histone tail acetylation and an open chromatin structure favoring the expression of cell differentiation or death genes. 5 HDACIs have shown significant preclinical activity in AML, and some, albeit limited, single-agent activity. 4 Notably, the Food and Drug Administration has recently granted Orphan Drug designation to the HDACI Pracinostat in AML. 6 Moreover, combining HDACIs, for example, Vorinostat, approved for CTCL, with standard cytotoxic regimens exhibits pronounced activity in AML. 7 HDACI lethality toward AML and other tumor types stems from multiple actions, including death receptor upregulation, reactive oxygen species generation and upregulation of pro-apoptotic proteins (for example, Bim), among others. 8 Recently, attention has focused on HDACI-mediated disruption of the DNA damage response (DDR). 9, 10 HDACIs downregulate Chk1, 11, 12 a kinase critical for all cell cycle checkpoints, 13 as well as DNA repair 14 in neoplastic cells. Notably, AML cells expressing mutant/fusion oncoproteins (for example, FLT3-ITD, leukemia-associated fusion proteins), which exhibit intrinsic DDR defects, 15 may be particularly vulnerable to HDACIs. 16 Evidence that HDACIs selectively induce DNA damage in neoplastic cells, 9 including leukemia cells, 17 impair the DDR (for example, checkpoints and repair) 8 and identification of Wee1, a protein kinase principally involved in regulation of the G2/M checkpoint by phosphorylating cyclin-dependent kinase 1 (cdc2/ Cdk1) at the inhibitory residue Y15, 18 as a novel therapeutic target in AML 19, 20 provide a rationale for the combined Wee1/HDAC inhibition in AML. Here we report that AZD1775, a highly selective small-molecule ATP-competitive Wee1 inhibitor currently undergoing clinical evaluation, 21 interacts synergistically with HDACIs in vitro and in vivo in AML cells in association with Wee1 inhibition, Chk1-mediated checkpoint abrogation, premature mitotic entry and increased DNA damage. Notably, cells expressing either wildtype (wt) or mutant p53, including those carrying FLT3 mutations (for example, FLT3-ITD), are highly susceptible to this strategy, as are primary AML cells but not normal hematopoietic cells. 1 Collectively, these findings argue that a strategy combining Wee1 with HDAC inhibitors warrants further evaluation in AML.
MATERIALS AND METHODS

Cells and reagents
Human AML cell lines U937 (p53-null), MV4-11 (p53-mutated, FLT3-ITD), MOLM-13 (p53 wt, FLT3-ITD) and OCI-AML3 (p53 wt) were maintained as before. 12 Experiments utilized logarithmically growing cells (3-6 × 10 5 cells/ml). Bone marrow or peripheral blood samples were obtained with informed consent from patients with histologically documented AML undergoing routine diagnostic procedures with Virginia Commonwealth University IRB approval (no. HM 12517). Primary AML samples (blasts 470% and viability 495%) and normal human cord blood CD34 + cells were isolated as described earlier. 12 Patient clinical, molecular and cytogenetic characteristics are reported in Supplementary Table S1 .
The selective Wee1 inhibitor AZD1775 and the pan-HDAC inhibitor Vorinostat (formerly SAHA) were provided by AstraZeneca (Wilmington, DE, USA) and Merck (Whitehouse Station, NJ, USA) through National Cancer Institute, NIH. SBHA was purchased from Calbiochem (San Diego, CA, USA). Reagents were formulated in dimethyl sulfoxide and stored at − 20°C. Final dimethyl sulfoxide concentrations wereo0.1%.
Next-generation sequencing (NGS) of primary AML samples
Primary AML samples (mononuclear cells) were analyzed by NGS using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Grand Island, NY, USA), which surveys hotspot regions of 50 oncogenes and tumorsuppressor genes. NGS analyses were conducted using the Ion Torrent targeted sequencing technology (Life Technologies).
Analysis of cell cycle and checkpoints
Cell cycle analysis by propidium iodide (PI) staining in the presence of RNase A was performed by flow cytometry (FCM) using the Modfit LT2.0 software (Verity Software House, Topsham, ME, USA) as described previously. 12 Premature mitotic entry was assessed as reported earlier. 22 Cells were fixed in ice-cold 70% ethanol and permeabilized with 0.25% Triton X-100 in phosphate-buffered saline, followed by staining with AlexaFluor 488-conjugated anti-phospho-histone H3 (p-H3, S10) antibody (Cell Signaling, Danvers, MA, USA) at 4°C in dark. After PI staining for cell cycle analysis as above, the percentage and cell cycle distribution of p-H3-positive cells was determined by FCM.
For G1/S and intra-S phase checkpoint assessment, the Click-iT EdU CellCycle 488-Red (7-aminoactinomycin D (7-AAD)) Assay Kit (Invitrogen, Grand Island, NY, USA) was used to monitor DNA replication through incorporation of the thymidine analogue 5-ethynyl 2-deoxyuridine (EdU, 10 μM, 30 min) into genomic DNA during DNA synthesis by FCM. 12 To monitor DNA replication and mitotic entry simultaneously, cells were labeled with EdU, followed by staining for p-H3 as above.
Immunofluorescence
Cytospin slides were fixed in 4% paraformaldehyde for 1 h, permeabilized in 0.25% Triton X-100 in phosphate-buffered saline, blocked in 1% bovine serum albumin and 2% fetal bovine serum in phosphate-buffered saline, followed by staining with AlexaFluor 488-conjugated anti-p-H3 antibody. 22 Slides were mounted using Vectashield containing 4,6-diamidino-2-phenylindole. Images were captured using a Zeiss LSM 700 confocal microscope (Zeiss, Oberkochen, Germany) or Olympus IX71 Research Inverted System Microscope with a DP73;17MP Color Camera (OLYMPUS AMERICA INC., Center Valley, PA, USA).
For double staining for EdU and p-H3, cytospin slides were prepared after pulse labeling with EdU, followed by immunofluorescence staining for p-H3 using secondary AlexaFluor 594-conjugated antibody (Cell Signaling).
Analysis of cell death, RNA interference and western blotting
See Supplementary Methods for analysis of cell death, RNA interference and western blotting.
Animal studies
Animal studies were approved by the VCU IACUC and were performed in accordance with the US Department of Agriculture and Department of Health and Human Services and the NIH. NOD/SCID-gamma mice (Jackson Laboratories, Sacramento, CA, USA) were subcutaneously inoculated in the flank with 5 × 10 6 luciferase-labeled U937 cells. After luciferase activity was detected, AZD1775 and Vorinostat were administrated by oral gavage (p.o.) or intraperitoneal injection, respectively. Control animals received equal volumes of vehicle. Mice were monitored every other day after luciferin intraperitoneal injection using an IVIS 200 imaging system (Xenogen Corporation, Alameda, CA, USA). Tumor size was measured by a caliper, and volumes were calculated using the formula (L × W 2 )/2, with L = length and W = width. Body weights were measured every other day throughout the study. When tumor size reached 2000 mm 3 or after other humane end points (for example, abscessed or necrotic tumors), mice were euthanized in accordance with the institutional guidelines.
Statistical analysis
Values represent the means ± s.d. for at least three independent experiments performed in triplicate. Significance of differences between the experimental variables was determined using the Student's t-test or one-way analysis of variance with Tukey-Kramer Multiple comparisons test (two-sided). The significance of P-values was o0.05 (*) and o 0.01 (**) wherever indicated. Analysis of synergism was performed by Median Dose-Effect analysis using the Calcusyn software (Biosoft, Ferguson, MO, USA). Kaplan-Meier survival analysis utilized the IBM SPSS Statistics software (Armonk, NY, USA).
RESULTS
AZD1775/HDACI co-administration reduces total and phosphorylated Wee1 and diminishes cdc2/Cdk1 Y15 phosphorylation in AML cells Exposure (24 h) to AZD1775 (100-500 nM) modestly reduced Wee1 phosphorylation on S642, an event occurring during S and G2 phases and required for 14-3-3 binding, 23 in various leukemia cells, including p53-null or -mutant U937 ( Figure 1a ) and MV4-11 (FLT-ITD, Figure 1b) , as well as p53-wt MOLM-13 (FLT3-ITD, Figure 1c ) and OCI-AML3 (Figure 1d ). The HDACIs Vorinostat or SBHA also modestly reduced S642 phosphorylation in certain cell lines (for example, MV4-11 and OCI-AML3). However, combined treatment profoundly diminished S642 phosphorylation of Wee1 in all the lines. Whereas AZD1775 or HDACIs alone had little effect, AZD1775/HDACI co-administration also reduced total Wee1 protein (Figures 1a-d ). Y15 phosphorylation of cdc2/Cdk1, a biomarker of Wee1 kinase activity, 24, 25 was then examined. AZD1775 by itself diminished cdc2/Cdk1 Y15 phosphorylation, and this effect was modestly but discernibly enhanced by HDACIs, although protein levels were unaffected (Figures 1a-d) . Notably, diminished cdc2/Cdk1 Y15 phosphorylation with combined treatment was observed as early as 8 h after drug administration (Supplementary Figure S1A) . Thus AZD1775 inactivates Wee1 in both p53 wt and mutant leukemia cells, an event enhanced by HDACIs and accompanied by pronounced cdc2/Cdk1 Y15 dephosphorylation.
AZD1775 interacts synergistically with HDACIs in AML cells carrying mutant p53 or FLT3-ITD Whereas p53 loss or mutation is relatively uncommon in AML (for example, 5-10%) 26 compared with FLT3 mutations (for example, 27%), 2 they occur more commonly in therapy-related AML (t-AML; for example, 40-50%) 27 and are associated with poor prognosis. 26 Effects of AZD1775 and HDACIs were evaluated in p53-null cells (U937) 12 or cells with p53 point mutations at codon 344 (MV4-11, which also expresses FLT3-ITD). 12 Notably, co-administration (24 h) of marginally toxic AZD1775 concentrations (for example, 50-750 nM) with minimally toxic and clinically relevant concentrations of Vorinostat (for example, 0.5-1.5 μM) strikingly induced apoptosis in both U937 (Figure 2a Figure S1D) . Sequential HDACI pretreatment (24 h) followed by AZD1775 also markedly increased apoptosis, comparable with simultaneous administrations, whereas the reverse sequence was less effective (data not shown).
Co-administration of AZD1775 and either Vorinostat (Figure 2c ) or SBHA (Supplementary Figure S1E) markedly increased caspase-9 cleavage/activation and poly ADP-ribose polymerase (PARP) degradation in U937 and MV4-11 cells, associated with significant reductions in colony formation (Figure 2d) . Finally, isobologram analysis yielded Combination Index (CI) values o1.0 in both cell lines, indicating synergism (Figure 2e ). Together, these findings suggest that targeting Wee1 by AZD1775 sharply potentiates HDACI lethality in p53-mutant AML cells, including those expressing FLT3-ITD.
The AZD1775/HDACI regimen is highly active in AML cells expressing wt p53 Responses to Wee1 inhibitors, particularly when combined with DNA-damaging agents 28 or radiation, 29 is enhanced in p53-deficient tumor cells, presumably due to reliance on the G2/M checkpoint when the G1/S checkpoint is impaired. 21 Parallel studies were therefore performed in leukemia cells expressing wt p53, including OCI-AML3 12 and MOLM-13 (which also expresses FLT3-ITD) 12 (Figure 3c ). Significantly, co-administration of HDACIs (for example, Vorinostat or SBHA) markedly increased caspase 9 cleavage/activation and PARP degradation (Figure 3d ), in p53-wt leukemia cells. Collectively, these findings indicate that, in contrast to settings in which AZD1775 potentiates genotoxic agent and radiation activity primarily in p53-deficient tumors, 28, 29 the AZD1775/HDACI regimen is effective in both p53-mutant and -wt leukemias.
HDACIs abrogate AZD1775-induced Chk1 activation and cdc2/Cdk1 T14 phosphorylation, accompanied by premature mitotic entry and DNA damage AZD1775 ± HDACI effects on activation of Chk1, a key regulator of multiple cell cycle checkpoints as well as DNA replication and repair, 13 was then examined. Notably, AZD1775 sharply increased Chk1 phosphorylation on three serine residues (S296, S317 and S345), essential for Chk1 activation, 30 in p53-deficient U937
Vor ( Figure S2D) ). Of note, reversal of both AZD1775-mediated Chk1 activation and cdc2/Cdk1 T14 phosphorylation by Vorinostat, accompanied by increased γH2A.X expression, occurred at an early interval (for example, 8 h; Supplementary Figure S1A) , considerably prior to obvious apoptosis induction (that is, 16 h Supplementary Figure S1D) , arguing that the former is unlikely to be a secondary event. These findings raise the possibility that Chk1 activation and cdc2/Cdk1 T14 phosphorylation represent compensatory responses to Wee1 inhibition and that HDACIs disrupt these events, triggering premature mitotic entry, DNA damage and cell death in both p53-wt and -deficient AML cells. Alternatively, western blotting analysis was performed to detect the cleavage of caspase-9 and PARP. CF = cleaved fragment. (d) After 24-h exposure to AZD1775 (U937, 500 nM; MV4-11, 250 nM) ± Vorinostat (U937, 1.5 μM; MV4-11, 0.5 μM), a soft-agar assay was performed to assess colony-formation capacity (**P o0.01). (e) Cells were exposed (24 h) to varying concentrations of AZD1775 and Vorinostat alone and in combination at a fixed ratio. At the end of this period, the percentage of Annexin V + cells was determined for each condition, and the Median Dose-Effect analysis was then employed to characterize the nature of the interaction between these agents. Combination Index (CI) values o1.0 denote a synergistic interaction. The results are representative of three separate experiments.
Combined Wee1/HDAC inhibition triggers mitotic lethality and abrogates the G1/S checkpoint Effects on cell cycle checkpoints were then examined, using the mitotic inhibitor Taxol as a control. Cell cycle analysis of U937 cells revealed that while HDACIs increased the G2/M sub-population, 33 this event was enhanced by AZD1775 as early as 8 h after drug treatment (Figure 5a , top, and Supplementary Figure S3A) . Notably, whereas both AZD1775 and HDACIs alone modestly increased the mitotic index (MI) at 8 h, reflected by positivity of S10 phosphorylated histone H3 (p-H3), combined exposure strikingly increased the p-H3 MI (for example, 3.4-and 3.7-fold increases for AZD1775/Vorinostat or AZD1775/SBHA, respectively; Figure 5a , bottom), consistent with premature mitotic entry at this early interval. However, while AZD1775 ± HDACIs clearly decreased S-phase cells, neither agent alone or in combination obviously affected DNA replication, manifested by a minimal increase in EdU-positive cells at 8 h (Supplementary Figures S3B  and C) . Interestingly, AZD1775/Vorinostat or AZD1775/SBHA cotreatment for 16 h sharply arrested cells in early S phase (Figure 5b , top, and Supplementary Figure S4A ) and increased newly replicated DNA incorporating EdU 34 ( Figure 5b , bottom, and Supplementary Figure S4B) , accompanied by persistent increases in premature mitotic entry (for example, increased p-H3 MI; Figure 5b , bottom, and Supplementary Figure S4C) . Fluorescence microscopy demonstrated robust increases in both p-H3-and EdU-positive cells after 16-h co-exposure to AZD1775 and Vorinostat or SBHA (Figure 5c and Supplementary Figure S4D) . Furthermore, confocal microscopy of AZD1775/HDACI-treated cells (16 h) revealed markedly aberrant mitosis characterized by multiple mitotic abnormalities, for example, anaphase bridging, mono-or multi-polar spindles, centrosome clustering and so on in p-H3-positive cells 22, 35 (Figure 5d ). Such findings indicate that AZD1775/HDACI co-treatment induces premature mitotic entry, aberrant mitosis and accumulation of early S-phase cells with increased de novo DNA replication and suggest that Wee1 and HDAC inhibitors interact reciprocally to disrupt both G2/M and G1/S checkpoints.
Wee1 shRNA knockdown significantly increases AML cell susceptibility to HDACIs, associated with premature mitotic entry To validate the functional significance of Wee1 inhibition on HDACI responses in leukemic cells, U937 Wee1 shRNA cells were employed (Figure 6a , inset; two clones designated D3 and E3). Notably, Wee1 knockdown significantly sensitized cells to SBHAand Vorinostat-induced apoptosis, compared with scrambled sequence controls (shNC; Figure 6a , Po 0.01 or 0.05 in all cases). In contrast to AZD1775, stable Wee1 knockdown did not discernibly affect cdc2/Cdk1 Y15 phosphorylation; however, Vorinostat or SBHA markedly reduced this inhibitory phosphorylation in Wee1 knockdown cells (Figure 6b ), similar to AZD1775 cotreatment ( Figure 1a ). This was accompanied by sharply increased histone H3 S10 phosphorylation, indicating premature mitotic entry, pronounced γH2A.X induction and increased PARP cleavage (Figure 6c ). These findings argue that Wee1 inhibition has a significant functional role in AZD1775/HDACI interactions in leukemia cells.
The AZD1775/HDACI regimen is active against primary AML blasts carrying various genetic aberrations and leukemia-initiating cellenriched populations but not against normal hematopoietic cells Parallel studies were performed in bulk populations of six primary AML samples (all ⩾ 70% blasts). In a representative study, AZD1775 alone had little effect, while Vorinostat (Figure 7a activity toward AML blasts. However, AZD1775/HDACI coexposure markedly increased Annexin V-positive (apoptotic) cells (for example, ⩾ 50-60%). Assessment of mitochondrial membrane potential (ΔΨm) loss (reduced DiOC 6 uptake) and cell death (7-AAD + ) confirmed enhanced lethality in five of the total six tested primary AML samples, while only one sample (patient no. 6) weakly displayed a loss of cell viability (Supplementary Figure S6) . These results were expressed as median responses in Figure 7b (P o 0.01 for the combination vs each agent alone). Additionally, genetic mutations were analyzed by NGS in five samples (Figure 7c) , of which the four responding samples (patient nos. 1-4) each carried four or five somatic mutations, including p53, FLT3, NRAS, KRAS, BRAF, PDGFRA, MET, STK11, SMARCB1 or APC. Notably, in these samples, patient nos. 1 and 2 expressed wt p53, while patient nos. 3 and 4 carried p53 mutations. Moreover, FLT3 mutations were found in 2/4 responding samples (patient nos. 2 and 4). However, the modestly responding sample (patient no. 6) exhibited only the favorable prognosis NPM1 mutation. These results argue that the AZD1775/HDACI regimen may be active against primary leukemia cells expressing either wt or mutant p53, as in leukemia cell lines.
Regimen activity was then examined in the primary AML CD34 + /CD38 − /CD123 + sub-population enriched for leukemia-initiating cells 19 ,36 using multicolor FCM. Whereas AZD1775 had moderate effects, HDACIs alone exhibited clear lethality. However, combined AZD1775/Vorinostat (Figure 7d ) or AZD1775/SBHA treatment (Supplementary Figure S5B) sharply increased the percentage of Annexin V-positive (apoptotic) cells (for example, 460-70%). Similar results were obtained in two additional primary AML samples (data not shown). In contrast, identical regimens exhibited minimal toxicity toward normal cord blood CD34 + cells (Figure 7a , bottom, and Supplementary Figure S5A, bottom) . Finally, as in leukemia cell lines, combined AZD1775/HDACI treatment of primary AML blasts also induced pronounced DNA damage (for example, γH2A.X expression) and apoptosis (for example, PARP degradation; Figure 7e ). Together, these findings indicate that the ability of AZD1775 to promote HDACI lethality can occur independently of p53 status in primary AML blasts, (24 h) with the indicated concentrations of AZD1775 ± Vorinostat or SBHA, after which western blotting analysis was performed to examine phosphorylation (S296, S317, S345) and protein levels of Chk1. (d-f) Alternatively, the mitotic entry marker histone H3 S10 phosphorylation, the double-strand break indicator γH2A.X, T14 phosphorylation of cdc2/Cdk1 and total protein levels were monitored in parallel.
including those bearing poor prognostic mutations, and also raise the possibility that this regimen targets primitive AML progenitors while sparing normal hematopoietic cells. Moreover, combined treatment significantly prolonged animal survival by Kaplan-Meier analysis (for example, median survival of ⩾ 40 days, compared with 31.5 or 30 days for AZD1775 or Vorinostat alone, respectively, P o 0.05; Figure 8d ). Notably, 3/5 mice in the combination group were killed because of humane end points (for example, abscessed or necrotic tumors), rather than tumor size ⩾ 2000 mm 3 . During the entire study, mice did not display significant body weight loss (that is, ⩾ 10% of initial weight; Supplementary Figure S7 ) or other signs of toxicity. Finally, western blotting analysis of tumor lysates revealed that combined AZD1775/Vorinostat treatment clearly reduced Wee1 S642 and CDK1 Y15 and T14 phosphorylation, accompanied by increased γH2A.X expression and PARP cleavage (Figure 8e) activity in vivo as well as in vitro, potentially through similar mechanisms.
DISCUSSION DDR deregulation in neoplastic cells has prompted therapeutic efforts to disrupt DNA-damage checkpoints to potentiate genotoxic agent lethality, 13 leading to the development of agents targeting Chk1, 13 ATM, 37 ATR 38 and, most recently, Wee1. 21 As Wee1 has a critical role in the G2/M DNA-damage checkpoint, 28 Wee1 inhibitors such as AZD1775 have been employed to improve the efficacy of DNA-damaging chemotherapeutic agents and ionizing radiation through mitotic lethality, 21 primarily in solid tumor malignancies. 25, [39] [40] [41] [42] [43] [44] [45] This strategy is based on preclinical reports that AZD1775 potentiates genotoxic agent 28 and ionizing radiation 29 activity, particularly in p53-deficient tumors, through mitotic lethality. 21 Wee1 also has critical roles in S-phase DNA replication (for example, replication fork stabilization), 18, 46 cell division timing 47 and DNA repair (for example, homologous recombination). 48 Recently, Wee1 has been identified as an AML target, and the potentiation of Ara-C or mammalian target of rapamycin inhibitor lethality by Wee1 inhibition has been reported in such cells. 19, 20, 49 Furthermore, perturbations in cell cycle-regulatory genes (including Cdks, cyclins and Cdk endogenous inhibitors) are frequent in AML (for example, 66%) and correlate with poor prognosis. 50 Additionally, aberrations of genes related to checkpoints (for example, ATM, ATR, Chk1, Chk2, Wee1) or DNA repair (for example, RAD51, BRCA1, BRCA2, MLH1 and so on) occur in 41% of AML patients. 50 In this context, HDACI mechanisms of action have also focused on DNA-damage induction through disruption of DNA-damage checkpoints and/or repair. 8 However, information concerning Wee1/HDAC inhibitor interactions is lacking in AML or other tumor types. Together, these considerations provide a rationale for exploring Wee1/HDAC inhibition in AML.
Wee1 inhibitor mechanisms of action initially focused on disruption of the G2/M checkpoint, which permits cells to repair genotoxic agent-mediated DNA damage before entry into mitosis for cell division.
28 G2/M checkpoint abrogation triggers premature mitotic entry and mitotic catastrophe. 28, 51 However, the role of Wee1 in the S-phase checkpoint, 52 which ensures proper DNA replication, 46 represents an additional mechanism by which Wee1 inhibitors promote cell death. HDACIs have also been reported to disrupt both G2/M-and S-phase checkpoints. 8 Notably, HDACI coadministration with AZD1775 enhanced Wee1 inactivation/downregulation and cdc2/Cdk1 Y15 dephosphorylation (activation), which, when unscheduled, triggers cell death. 53 Consistent with these actions, Wee1/HDACI co-exposure also induced premature mitotic entry, reflected by marked increases in histone H3 S10 phosphorylation and the p-H3 MI, 22 due to disruption of the G2/M checkpoint. 54 Significantly, these events occurred at early intervals (for example, 8 h) prior to apoptosis induction (for example, 16 h), and persisted over 24 h. Moreover, Wee1 knockdown also sharply increased HDACI lethality in association with similar events (for example, enhanced cdc2/Cdk1 Y15 dephosphorylation and DNA damage). Interestingly, combined treatment also increased early S-phase accumulation and newly replicated DNA (that is, EdU incorporation) at relatively late intervals (for example, 16 h), suggesting abrogation of the G1/S-phase checkpoint which prevents S-phase entry (that is, the G1/S transition) in the presence of DNA damage through inhibition of DNA replication initiation. 13 Finally, markedly aberrant mitoses (for example, monopolar or multipolar spindles, anaphase bridging, centrosome clustering and so on) were observed in co-treated cells, accompanied by robust DNA damage and cell death. Together, these findings argue that whereas Wee1 inhibition alone 55, 56 or in combination with genotoxic agents 25, 39, 41 disrupts the G2/M checkpoint, Wee1 and HDAC inhibitors interact reciprocally to disrupt both the G1/S and G2/M checkpoints. However, inasmuch as HDACIs disrupt multiple events of the DDR, 9,10 including downregulation of Chk1 11, 12 as well as DNA repair proteins, 14 the possibility that additional mechanism(s) implicated in the DDR might also contribute to synergism between HDAC and Wee1 inhibitors cannot be excluded. It is also possible that increased Combining Wee1 and HDAC inhibitors in AML L Zhou et al lethality (particularly in primary AML samples) in the present setting may not exclusively reflect apoptosis but may also stem from alternative forms of cell death. Several lines of evidence suggest that Wee1/HDAC inhibitor synergism involves Chk1. Although both Chk1 and Wee1 are involved in the G2/M checkpoint, 30 they share other, unrelated functions, that is, stabilization of replication forks and multiple mitotic events. 21, 57 Moreover, Chk1 phosphorylates and activates Wee1. 13, 58 In this regard, recent studies have demonstrated that combining Wee1 inhibitors (for example, AZD1775) with Chk1 inhibitors induces pronounced DNA damage (for example, increased γH2A.X levels) and apoptosis, 22, 45, 59 including in AML cells. 60 Such interactions have been related to the role of Chk1 in the G1/S checkpoint 13 or forced mitotic entry of S-phase cells. 22 Interestingly, Chk1 inhibition also promotes HDACI-mediated DNA damage and lethality in AML cells. 12 Consistent with earlier observations, 56, 60 AZD1775 clearly triggered Chk1 activation (for example, phosphorylation on all three critical activation sites, including S296, S317 and S345). 30 Of note, this event was accompanied by cdc2/Cdk1 phosphorylation on the inhibitory site T14. Whereas Wee1 primarily phosphorylates cdc2/Cdk1 Y15, T14 is preferentially phosphorylated by Myt1. 31 However, failure of AZD1775 to activate Myt1 suggests, albeit indirectly, that T14 phosphorylation stems from Chk1 activation through inhibition/ degradation of Cdc25, a phosphatase that dephosphorylates cdc2/ Cdk1 T14 and Y15 sites. 30 Collectively, these findings suggest that AZD1775-induced Chk1 activation, leading to cdc2/Cdk1 T14 phosphorylation, represents a compensatory response to Wee1 disruption that limits cdc2/Cdk1 activation and checkpoint abrogation. However, HDACIs not only enhanced Wee1 inhibition and Y15 dephosphorylation, they also sharply attenuated AZD1775-mediated T14 phosphorylation, presumably through downregulation/inactivation of Chk1. 11, 12 As a consequence, AZD1775/HDACI co-administration resulted in cdc2/Cdk1 dephosphorylation on both inhibitory Y15 and T14 sites, triggering full (and 'inappropriate') activation, thereby abrogating both G1/S and − /CD123 + population. (e) Western blotting analysis was performed to monitor γH2A.X levels and PARP degradation in one representative primary responding sample.
G2/M checkpoints and potentiating apoptosis. 53 Indeed, the early (for example, 8 h) T14 and Y15 dephosphorylation of cdc2/Cdk1 was accompanied by premature mitotic entry and G1/S checkpoint abrogation in cells co-exposed to AZD1775 and HDACIs. Thus, HDACIs, in addition to disrupting DNA repair, 14 may recapitulate Chk1 inhibitor actions in promoting Wee1 inhibitor lethality. 22 Although p53 mutations occur relatively rarely in de novo AML, they are more common in relapsed/refractory disease and are associated with poor prognosis. 26 In previous studies involving solid tumors, AZD1775 principally potentiated the lethality of genotoxic agents (for example, gemcitabine, 5-fluorouracil) 25, 41 or radiation 40 in p53-deficient cells. Of note, AZD1775 potentiates Ara-C lethality in both p53-wt and -deficient AML cell lines. 19 Consistent with the latter findings, AZD1775 enhanced HDACI lethality in p53-wt or -deficient leukemia cells to a roughly equivalent extent, as well as in primary AML blasts expressing either wt or mutant p53. Significantly, similar interactions occurred in leukemia cell lines expressing FLT3-ITD, which may reflect intrinsic homologous recombination repair defects, 15 as well as primary AML cells bearing FLT3 mutations. Collectively, these findings suggest that the Wee1/HDAC inhibitor strategy acts independently of p53 status and is effective against cells expressing mutant FLT3, a poor prognostic marker in AML.
In summary, the present findings indicate that genetic or pharmacological interruption of Wee1 function sharply potentiates the anti-leukemic activity of clinically relevant HDACIs (for example, Vorinostat) independently of p53 status, and argue that this interaction involves interference with both the G1/S and G2/M checkpoints, leading to robust induction of DNA damage, mitotic disruption and apoptosis. Significantly, similar interactions occur in primary AML blasts and primitive (that is, CD34 + /CD38 − /CD123 + ) progenitors, including those bearing multiple poor prognostic genetic mutations (for example, p53, FLT3), but not in normal hematopoietic cells. Importantly, in vivo administration of these agents was well tolerated and markedly reduced tumor burden and increased survival in vivo. Although preclinical studies justify ongoing initiatives employing Wee1 inhibitors to improve the activity of standard genotoxic agents in solid tumors (for example, http://clinicaltrials.gov/show/NCT02151292; http://clinicaltrials. gov/show/NCT02087176), the present findings provide a foundation for combining Wee1 inhibitors (for example, AZD1775) with HDACIs in hematopoietic malignancies, such as AML. Accordingly, efforts to develop this strategy are currently underway.
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